SPOTLIGHT: Takeda buying out TAP partner
The wire services have been buzzing with reports that Takeda is close to a deal to buy out Abbott Laboratories' 50 percent stake in TAP Pharmaceutical, a joint venture. The stake is worth anywhere from $3 billion to $5 billion and would boost Takeda's rankings among global pharma players from 17th to 14th. Report
Be the first to comment
More stories about Abbott Labs
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
